{"id":31326,"date":"2017-02-27T12:25:33","date_gmt":"2017-02-27T12:25:33","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=31326"},"modified":"2017-02-27T16:07:13","modified_gmt":"2017-02-27T16:07:13","slug":"no-increase-in-adverse-birth-outcomes-with-maternal-tdfftc-in-us-study","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/31326","title":{"rendered":"No increase in adverse birth outcomes with maternal TDF\/FTC in US study"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-medium wp-image-31226\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2017\/02\/NEW-CROI-LOGO-2017-241x300.png\" alt=\"New CROI logo 2017\" width=\"241\" height=\"300\" srcset=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2017\/02\/NEW-CROI-LOGO-2017-241x300.png 241w, https:\/\/i-base.info\/htb\/wp-content\/uploads\/2017\/02\/NEW-CROI-LOGO-2017.png 551w\" sizes=\"auto, (max-width: 241px) 100vw, 241px\" \/><\/p>\n<p><strong>Polly Clayden, HIV i-Base<\/strong><\/p>\n<p><strong>Among pregnant women with HIV in the US, use of tenofovir, emtricitabine, lopinavir\/ritonavir (TDF\/FTC\/LPV\/r) was not associated with increased risk of adverse infant birth outcomes when compared to zidovudine, lamivudine, LPV\/r (AZT\/3TC\/LPV\/r) or TDF, FTC, atazanavir\/ritonavir (TDF\/FTC\/ATV\/r).<\/strong><\/p>\n<p>In the PROMISE trial, infants of women randomised to TDF\/FTC\/ LPV\/r had elevated risk of very preterm birth, very low birth weight, and death compared to those randomised to AZT\/3TC\/LPV\/r.<\/p>\n<p>Data from two large prospective US cohort studies (IMPAACT P1025 and PHACS ) were used to compare risk of adverse birth outcomes for infants with in utero exposure to AZT\/3TC\/LPV\/r, TDF\/FTC\/LPV\/r, and TDF\/FTC\/ATV\/r. The results from this comparison were shown at CROI 2017.<\/p>\n<p>Exposure was classified by first regimen used during pregnancy. The investigators evaluated the risk of the following outcomes: preterm (&lt;37 weeks) and very preterm (&lt;34 weeks) birth, low (&lt;2,500 g) and very low (&lt;1,500 g) birth weight, composite adverse and severe adverse outcomes (outcomes above plus foetal loss, infant mortality).<\/p>\n<p>Of 4,646 enrolled infants, 128 (2.8%), 539 (11.6%) and 954 (20.5%) had mothers who received TDF\/FTC\/LPV\/r, TDF\/FTC\/ATV\/r and AZT\/3TC\/LPV\/r respectively. Table 1 shows risk of outcomes by initial ART regimen.<\/p>\n<table border=\"0\">\n<caption>Table 1. Risk of outcomes by initial ART regimen in pregnancy<\/caption>\n<tbody>\n<tr>\n<th scope=\"row\">1st regimen<\/th>\n<td>TDF\/FTC\/LPV\/r<\/td>\n<td>TDF\/FTC\/ATV\/r<\/td>\n<td>AZT\/3TC\/LPV\/r<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Preterm birth<\/th>\n<td>27 (21.4%)<\/td>\n<td>86 (16.1%)<\/td>\n<td>184 (19.5%)<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Very preterm birth<\/th>\n<td>5 (4.0%)<\/td>\n<td>26 (4.9%)<\/td>\n<td>44 (4.7%)<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Low birth weight<\/th>\n<td>30 (23.8%)<\/td>\n<td>86 (16.2%)<\/td>\n<td>175 (18.8%)<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Very low birth weight<\/th>\n<td>1 (0.8%)<\/td>\n<td>10 (1.9%)<\/td>\n<td>18 (1.9%)<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Adverse outcome<\/th>\n<td>36 (28.1%)<\/td>\n<td>127 (23.7%)<\/td>\n<td>256 (27.2%)<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Severe adverse outcome<\/th>\n<td>7 (5.5%)<\/td>\n<td>28 (5.2%)<\/td>\n<td>51 (5.4%)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>In crude and adjusted analyses, the investigators found TDF\/FTC\/LPV\/r was not associated with adverse birth outcomes compared to AZT\/3TC\/LPV\/r or TDF\/FTC\/ATV\/r. The study was underpowered to evaluate severe outcomes. TDF\/FTC\/LPV\/r use in pregnancy was uncommon in the two large US cohorts.<\/p>\n<p>Reference:<\/p>\n<p>Rough K et al. TDF\/FTC in pregnancy shows no increase in adverse infant birth outcomes in US cohorts. CROI 2017, Seattle. Poster abstract 779.<br \/>\n<a href=\"http:\/\/www.croiconference.org\/sessions\/tdfftc-pregnancy-shows-no-increase-adverse-infant-birth-outcomes-us-cohorts\">http:\/\/www.croiconference.org\/sessions\/tdfftc-pregnancy-shows-no-increase-adverse-infant-birth-outcomes-us-cohorts <\/a> (abstract and poster)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Polly Clayden, HIV i-Base Among pregnant women with HIV in the US, use of tenofovir, emtricitabine, lopinavir\/ritonavir (TDF\/FTC\/LPV\/r) was not associated with increased risk of adverse infant birth outcomes when compared to zidovudine, lamivudine, LPV\/r (AZT\/3TC\/LPV\/r) or TDF, FTC, atazanavir\/ritonavir &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,35],"tags":[236],"class_list":["post-31326","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pmtct-and-maternal-health","tag-croi-2017"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/31326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=31326"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/31326\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=31326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=31326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=31326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}